Lantus (insulin glargine) / Sanofi 
Welcome,         Profile    Billing    Logout  
 89 Diseases   30 Trials   30 Trials   3067 News 


«12345678910111213...2829»
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Enrollment closed:  Empagliflozin Effect on Glucose Toxicity (clinicaltrials.gov) -  Dec 3, 2021   
    P4,  N=50, Active, not recruiting, 
    It can be an ideal choice for clinicians in patients with poor blood glucose control with insulin. Not yet recruiting --> Active, not recruiting
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Trial primary completion date:  Empagliflozin Effect on Glucose Toxicity (clinicaltrials.gov) -  Oct 22, 2021   
    P4,  N=50, Not yet recruiting, 
    LY IGlar and IGlar had equivalent efficacy in glycemic control and similar safety profiles in Chinese patients with T1DM, when used in combination with mealtime insulin lispro. Trial primary completion date: Nov 2022 --> Feb 2023
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Humalog pen (insulin lispro) / Eli Lilly, NN1213 / Novo Nordisk
    Enrollment change, Trial withdrawal:  Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit (clinicaltrials.gov) -  Oct 11, 2021   
    P4,  N=0, Withdrawn, 
    All TAs delivered safe dose recommendations with minimal hypoglycemia, leading to a stable glucose control in the majority of subjects. N=100 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Semglee (insulin glargine biosimilar) / PiSA Farmaceutica, Biocon, Viatris, Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Journal:  In brief: Semglee - insulin glargine interchangeable with Lantus. (Pubmed Central) -  Oct 7, 2021   
    N=100 --> 0 | Not yet recruiting --> Withdrawn No abstract available
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management (clinicaltrials.gov) -  Sep 23, 2021   
    P4,  N=39, Terminated, 
    Active, not recruiting --> Completed | N=219 --> 333 N=160 --> 39 | Trial completion date: Feb 2022 --> Aug 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Aug 2021; Stopped after internal review
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment open, Combination therapy:  Afrezza (clinicaltrials.gov) -  Sep 21, 2021   
    P3,  N=264, Recruiting, 
    N=160 --> 39 | Trial completion date: Feb 2022 --> Aug 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Aug 2021; Stopped after internal review Not yet recruiting --> Recruiting
  • ||||||||||  Myalept (metreleptin) / Novelion
    [VIRTUAL] Reversal of metabolic derangement in patient with congenital generalized lipodystrophy treated with metreleptin () -  Aug 27, 2021 - Abstract #ESPE2021ESPE_445;    
    Despite receiving Fenofibrate 145 mg daily, triglycerides remained high...Insulin Lispro was stopped within 3 days and insulin Lantus dose was tapered rapidly to 5 units daily and then stopped 3 months later...The patient had complete reversal of hyperglycemia and hypertriglyceridemia and normalization of hypertransaminasemia with metreleptin monotherapy. The normalization of liver enzymes is promising for possible long-term prevention of liver cirrhosis, a serious and potentially fatal complication of severe fatty liver disease.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Aug 23, 2021   
    P3,  N=264, Not yet recruiting, 
    The normalization of liver enzymes is promising for possible long-term prevention of liver cirrhosis, a serious and potentially fatal complication of severe fatty liver disease. Trial completion date: Apr 2025 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Apr 2023
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Clinical, Journal:  Predictors of Self-Efficacy in Administering Insulin Injection. (Pubmed Central) -  Aug 20, 2021   
    The findings indicated that "knowledge of diabetes and insulin injection," "insulin injection skills," "senior high school or above education," and "diabetes duration" were predictors of self-efficacy in administering insulin injection, which explained 41% of the total variance in self-efficacy. Health care professionals can design relevant strategies for improving patient self-efficacy in administering insulin injection, thereby increasing patients' insulin self-injection abilities.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
    Enrollment open:  SAFEGUARD: Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-na (clinicaltrials.gov) -  Aug 11, 2021   
    P4,  N=222, Recruiting, 
    Health care professionals can design relevant strategies for improving patient self-efficacy in administering insulin injection, thereby increasing patients' insulin self-injection abilities. Not yet recruiting --> Recruiting
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis
    Clinical, Journal:  The complexities of insulin allergy: a case and approach. (Pubmed Central) -  Jul 31, 2021   
    Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective.
  • ||||||||||  Trial completion:  Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics (clinicaltrials.gov) -  Jul 30, 2021   
    P=N/A,  N=103951, Completed, 
    In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective. Active, not recruiting --> Completed
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    New P3 trial, Combination therapy:  Afrezza (clinicaltrials.gov) -  Jul 22, 2021   
    P3,  N=264, Not yet recruiting, 
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Trial completion date, Trial primary completion date:  Empagliflozin Effect on Glucose Toxicity (clinicaltrials.gov) -  Jul 20, 2021   
    P4,  N=50, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Mar 2022 --> Jun 2023 | Trial primary completion date: Nov 2019 --> Nov 2022
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes (clinicaltrials.gov) -  Jun 4, 2021   
    P4,  N=50, Completed, 
    Initiation of Gla-300 therapy significantly improved glycemic control and reduced the risk of hypoglycemia in patients with T2DM inadequately controlled with different basal or premix insulin therapy regimes. Recruiting --> Completed | N=100 --> 50 | Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Feb 2021
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Semglee (insulin glargine biosimilar) / PiSA Farmaceutica, Biocon, Viatris
    Journal:  A novel peptide design aids in the expression and its simplified process of manufacturing of Insulin Glargine in Pichia pastoris. (Pubmed Central) -  May 15, 2021   
    High cell density fermentation that gave a good yield of the SCP, a single step conversion to insulin glargine, enabled by a unique design of SCP and a distinct purification approach, has led to a simplified and economical manufacturing process of this important drug used to treat diabetes. KEY POINTS: • Novel concept for processing single chain precursor of insulin glargine • Simple and economic process for insulin glargine • Physicochemical characterization and animal Pharmacodynamics show similarity to Lantus.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Preclinical, Journal:  Insulin acutely increases agonist-induced airway smooth muscle contraction in human and rat. (Pubmed Central) -  May 14, 2021   
    Obesity-prone and resistant rats were fed a low-fat diet for 5 wk and treated with insulin (Lantus, 3 units/rat sc) 16 h before vagally induced bronchoconstriction was measured...Thus, insulin, acutely potentiated agonist-induced increase in intracellular calcium and airway smooth muscle contraction. These findings may explain why obese individuals with hyperinsulinemia are prone to airway hyperreactivity and give insights into future targets for asthma treatment.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Trial completion date, Trial primary completion date:  Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management (clinicaltrials.gov) -  Apr 22, 2021   
    P4,  N=160, Recruiting, 
    These findings may explain why obese individuals with hyperinsulinemia are prone to airway hyperreactivity and give insights into future targets for asthma treatment. Trial completion date: Apr 2021 --> Feb 2022 | Trial primary completion date: Mar 2021 --> Dec 2021
  • ||||||||||  Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
    Trial completion:  GLITTER 2: Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (clinicaltrials.gov) -  Apr 21, 2021   
    P3,  N=550, Completed, 
    The present review provides a comprehensive overview of benefits of watermelon for the treatment of various ailments. Active, not recruiting --> Completed